Citadel Advisors
SLS icon

Citadel Advisors’s SELLAS Life Sciences SLS Stock Holding History

Citadel Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9M Buy
449,800
+353,100
+365% +$1.58M ﹤0.01% 6164
2025
Q4 		$365K Buy
96,700
+31,300
+48% +$60.8K ﹤0.01% 9730
2025
Q3 		$105K Buy
65,400
+32,400
+98% +$57.7K ﹤0.01% 11823
2025
Q2 		$72.3K Buy
33,000
+6,700
+25% +$10.3K ﹤0.01% 11563
2025
Q1 		$28.4K Sell
26,300
-2,400
-8% -$2.85K ﹤0.01% 12872
2024
Q4 		$29.8K Sell
28,700
-46,000
-62% -$52.5K ﹤0.01% 12883
2024
Q3 		$93.4K Buy
74,700
+63,000
+538% +$77K ﹤0.01% 11219
2024
Q2 		$13.9K Buy
11,700
+10,100
+631% +$13.7K ﹤0.01% 12912
2024
Q1 		$1.62K Sell
1,600
-13,700
-90% -$11.5K ﹤0.01% 14108
2023
Q4 		$16.2K Sell
15,300
-1,800
-11% -$1.95K ﹤0.01% 12801
2023
Q3 		$28K Sell
17,100
-7,900
-32% -$12.5K ﹤0.01% 12338
2023
Q2 		$39.3K Sell
25,000
-22,900
-48% -$36.8K ﹤0.01% 12082
2023
Q1 		$68.5K Buy
47,900
+34,200
+250% +$84.6K ﹤0.01% 11769
2022
Q4 		$32.3K Buy
13,700
+3,000
+28% +$8.41K ﹤0.01% 12645
2022
Q3 		$22K Sell
10,700
-100
-0.9% -$276 ﹤0.01% 12039
2022
Q2 		$24K Sell
10,800
-10,600
-50% -$31.1K ﹤0.01% 12326
2022
Q1 		$143K Buy
+21,400
New +$125K ﹤0.01% 11912
2021
Q4 		– Sell
-23,900
Closed -$219K – 14682
2021
Q3 		$219K Sell
23,900
-9,200
-28% -$85.4K ﹤0.01% 11801
2021
Q2 		$367K Buy
33,100
+13,600
+70% +$133K ﹤0.01% 10781
2021
Q1 		$167K Buy
+19,500
New +$160K ﹤0.01% 11931
2018
Q1 		– Sell
-18
Closed -$7K – 8734
2017
Q4 		$7K Buy
18
+6
+50% +$2.9K ﹤0.01% 7904
2017
Q3 		$6K Buy
12
+3
+33% +$1.98K ﹤0.01% 7453
2017
Q2 		$8K Buy
+9
New +$7.83K ﹤0.01% 7382

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's SLS Position: Q1 2026 in Review

Citadel Advisors opened a new position in SELLAS Life Sciences (SLS) in Q1 2026: 64,641 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #10681 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SLS as recently as Q3 2025.

Citadel Advisors first reported a position in SLS in Q4 2016 and has held it in 24 quarters since. The position peaked at $505K in Q4 2024. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Citadel Advisors held 64,641 shares of SELLAS Life Sciences worth $273K as of Q1 2026.
  • SELLAS Life Sciences was a new Citadel Advisors position in Q1 2026.
  • SELLAS Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10681 holding.
  • Citadel Advisors first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 24 quarters since.
  • Citadel Advisors's SELLAS Life Sciences position peaked at $505K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.